Cardiac Biomarkers for Rapid Evaluation of Chest Pain
2001; Lippincott Williams & Wilkins; Volume: 104; Issue: 13 Linguagem: Inglês
10.1161/circ.104.13.1454
ISSN1524-4539
Autores Tópico(s)Cardiac Imaging and Diagnostics
ResumoHomeCirculationVol. 104, No. 13Cardiac Biomarkers for Rapid Evaluation of Chest Pain Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBCardiac Biomarkers for Rapid Evaluation of Chest Pain Christian W. Hamm, MD Christian W. HammChristian W. Hamm From the Kerckhoff Heart Center, Bad Nauheim, Germany. Originally published25 Sep 2001https://doi.org/10.1161/circ.104.13.1454Circulation. 2001;104:1454–1456Physicians caring for acute chest pain patients constantly maneuver between unnecessary admissions and premature discharges. The ECG is the most readily available tool for identifying patients with ST-segment elevation, who are likely to have myocardial infarctions and who should receive reperfusion treatment. Establishing the correct diagnosis in the patients without ST-segment elevation, however, can be much more challenging. Undetected infarctions remain a serious public health issue and represent the leading cause of malpractice cases in the emergency room setting.1 Prematurely discharged patients often have been seen by physicians with less professional experience. Such patients frequently have more atypical complaints and nondiagnostic ECG findings, are younger, and are at higher risk than admitted patients.1,2See p 1483Ruling out acute myocardial infarctions, however, is an incomplete strategy according to today's standards. The target has moved to risk stratification, with the objective being not only to detect evolving myocardial infarctions, but also to identify the patient who is at risk of developing a life-threatening cardiac event in the near future. For this task, the ECG has limited prognostic relevance because abnormalities are infrequent and are of low sensitivity and specificity. Only ST-segment depression, which is found in about one third of the patients, is associated with short- and long-term adverse outcome.3,4Biomarkers in the New GuidelinesIn recent years, novel biochemical markers have emerged that play a pivotal role in diagnosis, risk stratification, and guidance of treatment. Markers of inflammation, such as C-reactive protein, have been found helpful in predicting the long-term prognosis, whereas the improved markers of cell necrosis, mainly cardiac troponins, are valuable tools in the acute phase assessment.5 There is solid evidence from numerous studies that the unstable patient with elevated troponins has an ≈9-fold increased risk for myocardial infarction or death in the next 30 days.6 Consequently, the American College of Cardiology/American Heart Association guidelines7 as well as the European Society of Cardiology Task Force Report8 last year incorporated troponin measurements into their diagnostic algorithms for patients with acute coronary syndromes. However, many practical aspects for optimizing the sampling protocols in the emergency unit and for combining troponin measurements with other markers in the clinical routine setting still need to be clarified.There is general consent that a single test for troponins on the arrival of the patient to the hospital is insufficient because a single test can miss 10% to 15% of at-risk patients. The timing for the second test has not yet been clearly defined. The European Society of Cardiology recommends repeating troponin testing between 6 to 12 hours after arrival in the emergency unit.8 The American version asks for a repeat test 8 to 12 hours after the onset of pain—a minor, but sometimes decisive difference in perception in the work-up of the individual patient. Previous studies before the era of troponins had suggested a 12-hour rule-out strategy.9 Troponins have helped to shorten and to improve the diagnostic work-up. A prospective study using troponin T and troponin I bedside tests proposed an interval of 6 hours to identify high-risk patients.10 The study in this issue of Circulation by McCord et al11 goes even further and reduces the time to safely exclude myocardial infarctions to 90 minutes after presentation in the hospital by using a point-of-care test system combining creatine kinase (CK)-MB, troponin I, and myoglobin measurements. Undoubtedly, these results are provoking and will stimulate a new discussion.Myocardial Infarction RedefinedA key point in the discussion will relate to the fact that the gold standard for myocardial damage has changed and myocardial infarction has been redefined.12 The consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee has based the new definition on biochemical grounds (eg, troponins), a choice that was guided by the insight that troponins indicate irreversible cell damage.12,13 Although many physicians currently have conceptual difficulties with the translation of this paradigm change into clinical practice, the increased risk in patients with elevated troponin levels justifies this new perception. Consequently, our procedures for ruling out myocardial infarction need to be based on troponins, which are the more sensitive and specific cardiac markers and which may be elevated when all other markers are still normal.In the study by McCord et al,11 the traditional CK-MB standard is still used to determine that a patient has had a myocardial infarction. Accordingly, diagnostic sensitivity and negative predictive values, as presented by McCord et al,11 must be interpreted against the new background. Today's emergency room triage does not end by ruling out CK-MB–elevation myocardial infarctions but rather must be extended to the patient with elevated troponins. The purpose is not only to comply with the new myocardial infarction definition, but more importantly, to identify the patient who is at risk for a serious coronary event in the near future. Therefore, safe discharge of the chest pain patient is not advised before the troponin measurements according to the currently valid sampling guidelines are available.7,8How Many Markers?Another unresolved issue addressed in the study by McCord et al11 relates to the question of what we gain in diagnostic accuracy when multiple markers are used. The National Academy of Clinical Biochemistry recommends the use of an early (within 6 hours' rise) and definite marker for establishing the diagnosis of myocardial infarction.14 Troponins are today the gold standard for detecting myocardial cell necrosis and therefore must be measured.13 Qualitative (positive/negative) and quantitative point-of-care test devices for troponin I as well troponin T have been shown to deliver reliable results.10,11,15 Myoglobin is released earlier in acute myocardial infarction but lacks cardiac specificity. The combination of both markers therefore is appealing, and the data of McCord et al11 demonstrate that this test system is producing reliable results. However, the optimistic results of McCord et al11 regarding myoglobin are not shared by another recent study involving 6352 patients with relatively early presentation to the hospital (median, <3 hours).16 The difference in results may be related to different analytical techniques and cut-offs, but it could also be caused by the patients' relatively late arrival to the hospital (median, 4.3 hours) in the study by McCord et al.11 It appears that the value of adding myoglobin to diagnostic work-up programs is greatest in the time window of 4 to 6 hours after the onset of pain.17Elevated myoglobin levels may be helpful for early triage of the level of care but, in contrast to troponins, have so far no proven implications for treatment. There is no clear indication for fibrinolytics without ST elevation or new left bundle-branch block.18 A patient with elevated myoglobin levels may be a candidate for immediate coronary angiography to clarify the condition; however, invasive facilities are neither available everywhere nor available around the clock, and apparently are not often used in this scenario.16 Therefore, patients generally will have to wait ≥6 hours for the troponin results that complete the risk stratification protocol.Myoglobin can be helpful for detecting reinfarction in patients with post-infarction angina when troponins are still elevated. Measurement of CK-MB may be performed because it is an inexpensive procedure and still provides a kind of familiar back-up safety. For risk stratification, however, CK-MB and myoglobin play no role. Therefore, it may be suggested for the future that resources be saved for an additional marker of inflammation, such as C-reactive protein, that allows for the estimation of long-term risk. For example, a patient with normal markers of myocardial cell necrosis but elevated C-reactive protein may be treated more aggressively with statins.19 More evidence will emerge in the coming years to elucidate this new field.Point-of-Care TestingThere is no question that point-of-care testing for biochemical markers is of great advantage when valuable time can be saved. Prerequisite is that the off-site measurement must be as accurate as it would be if it were performed by automated analyzers in a central laboratory. In the study by McCord et al,11 the time gained by point-of-care testing was 47 minutes. However, the central laboratory required 71 minutes to provide results, which is far from the 30 to 60 minutes recommended by the ACC/AHA guidelines.7 The National Academy of Clinical Biochemistry advises the implementation of point-of-care test systems if the hospital logistics cannot consistently deliver cardiac marker results within 1 hour.14 Provided the patient stabilizes clinically, minor time delays may not be as critical as in ST-elevation myocardial infarction. Recent study data indicate that in the case of elevated troponins, glycoprotein IIb/IIIa antagonists are most effective in preventing early complications.20–22 Coronary angiography and invasive strategies should be scheduled for patients with elevated troponins within a time window of 48 hours to improve long-term outcome.23PerspectivesDiagnostic strategies in patients with acute chest pain have to be reliable and simple. The objective is to reduce mortality and morbidity by initiating the best therapy. The ECG allows the exclusion of acute myocardial infarctions requiring immediate therapeutic response. Troponins can identify high-risk coronary patients that should be treated with glycoprotein IIb/IIIa antagonists and referred for invasive evaluation at earliest convenience. Common diagnostic sense is necessary to detect other noncoronary but critical conditions such as dissecting aortic aneurysms. Other biochemical markers are nice to have but will not reduce the time for observation. Even under the best circumstances it will still take 6 to 12 hours to reliably exclude high-risk conditions. The achievements in recent years with regard to risk stratification have been enormous, and the search for new markers will continue. A rise in myoglobin levels means that substantial amounts of myocardium are going into necrosis. Elevated troponins also indicate irreversible cell injury, and even if only a few cells are affected, we should not rest before we find ways to detect this beforehand.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Christian W. Hamm, MD, Kerckhoff Heart Center, Benekestrasse 2-8, D-61231 Bad Nauheim, Germany. E-mail [email protected] References 1 Rusnak RA, Stair TO, Hansen K, et al. Litigation against the emergency physician: common features in cases of missed myocardial infarction. Ann Emerg Med. 1989; 18: 1029–1034.CrossrefMedlineGoogle Scholar2 Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med. 2000; 342: 1163–1170.CrossrefMedlineGoogle Scholar3 Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999; 281: 707–713.CrossrefMedlineGoogle Scholar4 Kaul P, Fu Y, Chang W-C, et al. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. J Am Coll Cardiol. 2001; 38: 64–71.CrossrefMedlineGoogle Scholar5 Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation. 2000; 102: 118–122.LinkGoogle Scholar6 Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J. 2000; 140: 917–927.CrossrefMedlineGoogle Scholar7 Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. Circulation. 2000; 102: 1193–1209.CrossrefMedlineGoogle Scholar8 Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 2000; 21: 1406–1432.CrossrefMedlineGoogle Scholar9 Lee TH, Juarez G, Cook EF, et al. Ruling out acute myocardial infarction: a prospective multicenter validation of a 12-hour strategy for patients at low risk. N Engl J Med. 1991; 324: 1239–1246.CrossrefMedlineGoogle Scholar10 Hamm CW, Goldmann B, Heeschen C, et al. Emergency room triage of patients with acute chest pain based on rapid testing for troponin T or troponin I. N Engl J Med. 1997; 337: 1648–1653.CrossrefMedlineGoogle Scholar11 McCord J, Nowak RM, McCullough PA, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation. 2001; 104: 1483–1488.CrossrefMedlineGoogle Scholar12 The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J. 2000; 21: 1502–1513.CrossrefMedlineGoogle Scholar13 Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to troponin standard. Circulation. 2000; 102: 1216–1220.CrossrefMedlineGoogle Scholar14 Wu AH, Apple FS, Gibler B, et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem. 1999; 5: 1104–1121.Google Scholar15 Müller-Bardorff M, Rauscher T, Kampmann M, et al. Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing. Clin Chem. 1999; 45: 1002–1008.CrossrefMedlineGoogle Scholar16 Gibler WB, Hoekstra JW, Weaver WD, et al. A randomized trial of the effects of early cardiac serum marker availability on reperfusion therapy in patients with AMI. J Am Coll Cardiol. 2000; 36: 1500–1506.CrossrefMedlineGoogle Scholar17 Jernberg T, Lindahl B, James S, et al. Comparison between strategies using creatine kinase-MB (mass), myoglobin, and troponin T in the early detection or exclusion of acute myocardial infarction in patients with chest pain and a non-diagnostic electrocardiogram. Am J Cardiol. 2000; 86: 1367–1371.CrossrefMedlineGoogle Scholar18 Fibrinolytic therapy trialists' (FTT) collaborative group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994; 343: 311–318.CrossrefMedlineGoogle Scholar19 Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA. 2001; 285: 1711–1718.CrossrefMedlineGoogle Scholar20 Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med. 1999; 340: 1623–1629.CrossrefMedlineGoogle Scholar21 Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for risk stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999; 354: 1757–1762.CrossrefMedlineGoogle Scholar22 Newby LK, Ohman EM, Christenson RH, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. Circulation. 2001; 103: 2891–2896.CrossrefMedlineGoogle Scholar23 Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001; 344: 1879–1887.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByHachey B, Kontos M, Newby L, Christenson R, Peacock W, Brewer K and McCord J (2017) Trends in Use of Biomarker Protocols for the Evaluation of Possible Myocardial Infarction, Journal of the American Heart Association, 6:9, Online publication date: 22-Sep-2017. Fathil M, Md Arshad M, Ruslinda A, Nuzaihan M.N. M, Gopinath S, Adzhri R and Hashim U (2016) Progression in sensing cardiac troponin biomarker charge transductions on semiconducting nanomaterials, Analytica Chimica Acta, 10.1016/j.aca.2016.06.012, 935, (30-43), Online publication date: 1-Sep-2016. Naz S, Calderón Á, García A, Gallafrio J, Mestre R, González E, de Cabo C, Delgado M, Balanza J, Simionato A, Vaeza N, Barbas C and Rupérez F (2015) Unveiling differences between patients with acute coronary syndrome with and without ST elevation through fingerprinting with CE-MS and HILIC-MS targeted analysis, ELECTROPHORESIS, 10.1002/elps.201500169, 36:18, (2303-2313), Online publication date: 1-Sep-2015. Lee I, Luo X, Cui X and Yun M (2011) Highly sensitive single polyaniline nanowire biosensor for the detection of immunoglobulin G and myoglobin, Biosensors and Bioelectronics, 10.1016/j.bios.2011.01.001, 26:7, (3297-3302), Online publication date: 1-Mar-2011. Lewandrowski K (2009) Point-of-Care Testing for Cardiac Markers in Acute Coronary Syndromes and Heart Failure, Clinics in Laboratory Medicine, 10.1016/j.cll.2009.06.007, 29:3, (561-571), Online publication date: 1-Sep-2009. Godkar D, Bachu K, Dave B, Niranjan S and Khanna A (2008) B-Type Natriuretic Peptide (BNP) and ProBNP: Role of Emerging Markers to Guide Therapy and Determine Prognosis in Cardiovascular Disorders, American Journal of Therapeutics, 10.1097/MJT.0b013e31815af96f, 15:2, (150-156), Online publication date: 1-Mar-2008. Gupta S and de Lemos J (2007) Use and Misuse of Cardiac Troponins in Clinical Practice, Progress in Cardiovascular Diseases, 10.1016/j.pcad.2007.01.002, 50:2, (151-165), Online publication date: 1-Sep-2007. Storrow A, Lindsell C, Collins S, Fermann G, Blomkalns A, Williams J, Goldsmith B and Gibler W (2006) Emergency Department Multimarker Point-of-care Testing Reduces Time to Cardiac Marker Results Without Loss of Diagnostic Accuracy, Point of Care: The Journal of Near-Patient Testing & Technology, 10.1097/01.poc.0000232334.13428.7a, 5:3, (132-136), Online publication date: 1-Sep-2006. Cucchiara B, Messe S, Taylor R, Pacelli J, Maus D, Shah Q and Kasner S (2006) Is the ABCD Score Useful for Risk Stratification of Patients With Acute Transient Ischemic Attack?, Stroke, 37:7, (1710-1714), Online publication date: 1-Jul-2006. Oliveira J, Sevanian A, Rodrigues R, Apolinário E and Abdalla D (2006) Minimally modified electronegative LDL and its autoantibodies in acute and chronic coronary syndromes, Clinical Biochemistry, 10.1016/j.clinbiochem.2006.05.002, 39:7, (708-714), Online publication date: 1-Jul-2006. Wu A (2006) Point-of-Care Testing for Conventional Cardiac Markers, Point of Care: The Journal of Near-Patient Testing & Technology, 10.1097/00134384-200603000-00006, 5:1, (20-24), Online publication date: 1-Mar-2006. Fácila L, Bertomeu V, Núñez J, Sanchis J, Bodí V, Consuegra L, José Bosch M, Roselló A, Martínez Á, Blasco M and Llàcer À (2006) Influencia del antecedente de hipertensión arterial en los pacientes ingresados por síndrome coronario agudo sin elevación del segmento ST, Medicina Clínica, 10.1157/13084019, 126:4, (121-124), Online publication date: 1-Feb-2006. Ruiz-Ros V, Sanchis-Forés J, Bodí-Peris V, Núñez-Villota J, Gómez-Monsoliu C, José Bosch-Campos M, Ruiz-Aguilar C and Llàcer-Escorihuela Á (2006) Valor predictivo de la presentación clínica del dolor torácico en el diagnóstico de los síndromes coronarios agudos, Medicina Clínica, 10.1157/13083322, 126:1, (1-4), Online publication date: 1-Jan-2006. Amsterdam E and Deedwania P (2015) Bedside evaluation of cardiac markers, Postgraduate Medicine, 10.3810/pgm.2005.09.1703, 118:3, (15-22), Online publication date: 1-Sep-2005. DeVon H and Ryan C (2005) Chest Pain and Associated Symptoms of Acute Coronary Syndromes, The Journal of Cardiovascular Nursing, 10.1097/00005082-200507000-00006, 20:4, (232-238), Online publication date: 1-Jul-2005. Bodı́ V, Sanchis J, Llàcer À, Fácila L, Núñez J, Bertomeu V, Pellicer M and Chorro F (2005) Risk stratification in non-ST elevation acute coronary syndromes, International Journal of Cardiology, 10.1016/j.ijcard.2003.10.046, 98:2, (277-283), Online publication date: 1-Feb-2005. Bodí V, Sanchis J, Llàcer À, Fácila L, Núñez J, Pellicer M, Bertomeu V, Ruiz V and Chorro F (2005) Multimarker risk strategy for predicting 1-month and 1-year major events in non–ST-elevation acute coronary syndromes, American Heart Journal, 10.1016/j.ahj.2004.05.053, 149:2, (268-274), Online publication date: 1-Feb-2005. Jaffe A and Katus H (2004) Acute Coronary Syndrome Biomarkers, Circulation, 110:2, (104-106), Online publication date: 13-Jul-2004. Zarich S, Bradley K, Mayall I and Bernstein L (2004) Minor elevations in troponin T values enhance risk assessment in emergency department patients with suspected myocardial ischemia: analysis of novel troponin T cut-off values, Clinica Chimica Acta, 10.1016/j.cccn.2004.01.020, 343:1-2, (223-229), Online publication date: 1-May-2004. Svensson L, Axelsson C, Nordlander R and Herlitz J (2004) Prognostic value of biochemical markers, 12-lead ECG and patient characteristics amongst patients calling for an ambulance due to a suspected acute coronary syndrome, Journal of Internal Medicine, 10.1111/j.1365-2796.2004.01322.x, 255:4, (469-477), Online publication date: 1-Apr-2004. James S, Lindahl B, Armstrong P, Califf R, Simoons M, Venge P and Wallentin L (2004) A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes, International Journal of Cardiology, 10.1016/S0167-5273(03)00157-8, 93:2-3, (113-120), Online publication date: 1-Feb-2004. Bodí V, Sanchis J, Llàcer À, Fácila L, Núñez J, Pellicer M, Bertomeu V, Ruiz V, García D and Chorro F (2004) Valor independiente de la proteína C reactiva para predecir acontecimientos mayores al primer mes y al año en los síndromes coronarios agudos sin elevación del ST, Medicina Clínica, 10.1016/S0025-7753(04)75313-0, 122:7, (248-252), Online publication date: 1-Jan-2004. James S, Armstrong P, Califf R, Simoons M, Venge P, Wallentin L and Lindahl B (2003) Troponin t levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the gusto-iv trial, The American Journal of Medicine, 10.1016/S0002-9343(03)00348-6, 115:3, (178-184), Online publication date: 1-Aug-2003. Di Serio F, Antonelli G, Trerotoli P, Tampoia M, Matarrese A and Pansini N (2003) Appropriateness of point-of-care testing (POCT) in an emergency department, Clinica Chimica Acta, 10.1016/S0009-8981(03)00184-0, 333:2, (185-189), Online publication date: 1-Jul-2003. Lebar Bajec I, Trunk P, Oseli D and Zimic N (2003) Virtual coronary cineangiography, Computers in Biology and Medicine, 10.1016/S0010-4825(02)00095-1, 33:3, (293-302), Online publication date: 1-May-2003. Meier R, van Griensven M, Pape H, Krettek C, Chawda M and Seekamp A (2003) Effects of Cardiac Contusion in Isolated Perfused Rat Hearts, Shock, 10.1097/00024382-200302000-00006, 19:2, (123-126), Online publication date: 1-Feb-2003. Kaul P, Newby L, Fu Y, Hasselblad V, Mahaffey K, Christenson R, Harrington R, Ohman E, Topol E, Califf R, Van de Werf F and Armstrong P (2003) Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients, Journal of the American College of Cardiology, 10.1016/S0735-1097(02)02824-3, 41:3, (371-380), Online publication date: 1-Feb-2003. Arntz Y, Seelig J, Lang H, Zhang J, Hunziker P, Ramseyer J, Meyer E, Hegner M and Gerber C (2002) Label-free protein assay based on a nanomechanical cantilever array, Nanotechnology, 10.1088/0957-4484/14/1/319, 14:1, (86-90), Online publication date: 1-Jan-2003. Bodí V, Sanchis J, Llácer À, Fácila L, Núñez J, Pellicer M, Bertomeu V, Ruiz V and Chorro F (2003) Indicadores pronósticos del síndrome coronario agudo sin elevación del segmento ST, Revista Española de Cardiología, 10.1016/S0300-8932(03)76973-5, 56:9, (857-864), Online publication date: 1-Jan-2003. Pascual Figal D, Noguera Velasco J, Ródenas Checa J, Murcia Alemán T, Martínez Cadenas J, Ferrándiz Gomis R, Martínez Hernández P and Valdés Chávarri M (2003) El dolor torácico en la práctica clínica hospitalaria: repercusión clínica y asistencial del uso rutinario de troponinas, Revista Española de Cardiología, 10.1016/S0300-8932(03)76820-1, 56:1, (43-48), Online publication date: 1-Jan-2003. Collinson P (2003) Cardiac Marker Measurement by Point-of-Care Testing Cardiac Markers, 10.1007/978-1-59259-385-9_12, (199-212), . Krause E, Rabitzsch G and Noll F (2003) Early Detection of Ischemic Myocardial Damage by Glycogen Phosphorylase Isoenzyme BB: A Biomarker for Evaluation of Chest Pain and Evolving Infarction in Patients Myocardial Ischemia and Preconditioning, 10.1007/978-1-4615-0355-2_35, (519-532), . Börjesson M and Mannheimer C (2002) Chest pain: an update, Current Opinion in Anaesthesiology, 10.1097/00001503-200210000-00016, 15:5, (569-574), Online publication date: 1-Oct-2002. Panteghini M (2002) The Measurement of Cardiac Markers, American Journal of Clinical Pathology, 10.1309/RNTM-05T3-TWBX-V0NU, 118:3, (354-361), Online publication date: 1-Sep-2002. Siegel A (2002) Role for On-site Point-of-Care Testing in the Emergency Care of Athletes With Exercise-Associated Collapse, Point of Care: The Journal of Near-Patient Testing & Technology, 10.1097/01.POC.0000023481.69463.85, 1:3, (132-134), Online publication date: 1-Sep-2002. Siegel A (2002) Role for On-site Point-of-Care Testing in the Emergency Care of Athletes With Exercise-Associated Collapse, Point of Care: The Journal of Near-Patient Testing & Technology, 10.1097/00134384-200209000-00002, 1:3, (132-134), Online publication date: 1-Sep-2002. September 25, 2001Vol 104, Issue 13 Advertisement Article InformationMetrics https://doi.org/10.1161/circ.104.13.1454PMID: 11571234 Originally publishedSeptember 25, 2001 Keywordsmyocardial infarctionmyoglobintroponinEditorialsdiagnosisPDF download Advertisement
Referência(s)